Form 4: Dexcom Executive Matthew Dolan Reports Stock Grant and Holdings

Executive Vice President of Strategy and Corporate Development at Dexcom, Matthew Vincent Dolan, reports the acquisition of 21,711 shares of restricted stock units.

Summary

• Matthew Vincent Dolan, EVP of Strategy and Corporate Development at Dexcom, filed a Form 4.
• The filing reports a transaction on March 8, 2024, where Dolan acquired 21,711 shares of common stock in the form of restricted stock units.
• These restricted stock units were granted at a price of $0.00 and vest in three equal annual installments from the date of grant.
• Following the reported transaction, Dolan beneficially owns 55,280 shares of Dexcom common stock, including 40,075 unvested restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to executive compensation, and does not contain information that would significantly impact investor sentiment positively or negatively.

Future Outlook

The document does not contain any specific forward-looking statements regarding Dexcom's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity holdings of key personnel.

Comparison to Industry Standards

• Executive compensation packages often include grants of restricted stock units that vest over time.
• The vesting schedule of three equal annual installments is a common practice.
• Companies like Medtronic, Abbott, and Boston Scientific also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• Shareholders are informed about executive compensation practices.
• Employees may be indirectly affected by the perceived fairness of executive compensation.

Key Dates